Clinical Trial: The Effects of Gevokizumab in Corticosteroid-resistant Subjects With Autoimmune Inner Ear Disease
Study Status: Completed
Recruit Status: Completed
Study Type: Interventional
Official Title: An Open-label Study of the Effects of Gevokizumab in Corticosteroid-resistant Subjects With Autoimmune Inner Ear Disease
Brief Summary: The purpose of this study is to determine if gevokizumab therapy may be an alternate therapy in patients with steroid resistant Autoimmune Inner Ear Disease.
Detailed Summary:
Sponsor: XOMA (US) LLC
Current Primary Outcome: Improved hearing threshold, as defined by an improvement in either the PTA (Pure Tone Average) of >=5 dB (Decibel), or 12% in the WRS (Word Recognition Score) [ Time Frame: Day 28 to Day 84 ]
Original Primary Outcome: Same as current
Current Secondary Outcome:
Original Secondary Outcome:
Information By: XOMA (US) LLC
Dates:
Date Received: September 20, 2013
Date Started: August 2013
Date Completion:
Last Updated: February 2, 2016
Last Verified: February 2016